Narzi Pharmaceuticals Private Limited
About Narzi Pharmaceuticals Private Limited
Data last updated:
Narzi Pharmaceuticals Private Limited is a private limited company based in Nalbari, Assam, India, recognised as a startup by DPIIT. It operates in the service-based operations segment of the business services sector. It was incorporated on 29 December 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Guwahati, under CIN U74999AS2017PTC018293. Its GSTIN is 18AAFCN8889C1ZY (Assam).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹4.75 Lakh. It is led by directors including Faruk Choudhury and Jahangir Hussain.
Its last annual general meeting (AGM) was held on 30 September 2022, and its latest financial statements are for the year ended 31 March 2022. The registered office is at H/O Amzad Hussain Plot No.66 Daulasal Mouza – Pachim Bharkhetri, Nalbari, Assam, India – 781312.
As per the financials filed for FY 2022, the company reported a revenue of ₹15.51 Lakh, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹6,134 (net margin 0.4%) and EBITDA of ₹11,448 (EBITDA margin 0.7%). Revenue has grown at a compounded annual rate (CAGR) of 51% over three years.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressH/O Amzad Hussain Plot No.66 Daulasal Mouza – Pachim Bharkhetri, Nalbari, Assam, India – 781312
- IndustryBusiness Services, Other Services, Miscellaneous Business Activities
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Narzi Pharmaceuticals Private Limited
The main business activity of Narzi Pharmaceuticals is trade. In detail, this covers wholesale trading and retail trading. 2 activity segments are registered with the MCA.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
| G | Trade | G2 | Retail Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Narzi Pharmaceuticals Private Limited FY 2022 filings available
Narzi Pharmaceuticals Private Limited reported revenue of ₹15.51 Lakh (up 1634% YoY) for FY 2022.
Compounded Annual Growth Rate (CAGR) of Narzi Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 51% over three years. EBITDA rose 110% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Narzi Pharmaceuticals Private Limited
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹11,448 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹6,134 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Narzi Pharmaceuticals Private Limited
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0.7% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 0.4% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Narzi Pharmaceuticals are in the company report.
Financial statements from FY 2018
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Narzi Pharmaceuticals Private Limited
Narzi Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Regera Ventures Private Limited | ₹15.6 Lakh (FY 2024) | •••• | •••• | 365.0% | •••• | Mumbai, Maharashtra, India |
| Revolutionlife Pharmaceuticals Private Limited | ₹15.53 Lakh (FY 2020) | •••• | •••• | 41.0% | •••• | Lucknow, Uttar Pradesh, India |
| Externa Pharmaceuticals Private Limited | ₹15.53 Lakh (FY 2025) | •••• | •••• | 6502.0% | •••• | Nagpur, Maharashtra, India |
| PGRS New Life Pharma Private Limited | ₹15.52 Lakh (FY 2021) | •••• | •••• | -58.0% | •••• | Badli, Haryana, India |
| Orca Labs Private Limited | ₹15.52 Lakh (FY 2025) | •••• | •••• | •••• | Visakhapatnam, Andhra Pradesh, India | |
| Narzi Pharmaceuticals Private Limited this company | ₹15.51 Lakh (FY 2022) | •••• | •••• | 1634.0% | •••• | Nalbari, Assam, India |
| Iffat Pharmaceuticals Private Limited | ₹15.49 Lakh (FY 2024) | •••• | •••• | -8.0% | •••• | Mumbai, Maharashtra, India |
| Rowa Health Care Private Limited | ₹15.47 Lakh (FY 2025) | •••• | •••• | -9.0% | •••• | Patna, Bihar, India |
| Tnova Pharmaceutical Private Limited | ₹15.47 Lakh (FY 2024) | •••• | •••• | 63.0% | •••• | Bangalore, Karnataka, India |
| Diar Pharmaceuticals Private Limited | ₹15.46 Lakh (FY 2022) | •••• | •••• | -19.0% | •••• | New Delhi, Delhi, India |
| Drhealth Pharmaceuticals Private Limited | ₹15.44 Lakh (FY 2021) | •••• | •••• | -58.0% | •••• | Palghar West, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Narzi Pharmaceuticals by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Narzi Pharmaceuticals Private Limited
Narzi Pharmaceuticals has 3 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Faruk Choudhury | Director | 31 May 2021 | 5 Years 4 Months | Current |
| Jahangir Hussain | Director | 29 Dec 2017 | 8 Years 9 Months | Current |
| Amzad Hussain | Director | 29 Dec 2017 | 8 Years 9 Months | Current |
Ownership and Shareholding of Narzi Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Narzi Pharmaceuticals Private Limited
Narzi Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Narzi Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Narzi Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Narzi Pharmaceuticals Private Limited
Narzi Pharmaceuticals Private Limited has 3 board changes on record since 2017: 3 appointments. The latest: Faruk Choudhury was appointed as Director on 31 May 2021.
Credit Ratings, Litigation & Regulatory Alerts for Narzi Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Narzi Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Narzi Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Narzi Pharmaceuticals Private Limited
Narzi Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 18AAFCN8889C1ZY | Assam | Active | 06 Aug 2018 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Narzi Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Narzi Pharmaceuticals Private Limited
Narzi Pharmaceuticals is an active private limited company based in Nalbari, Assam, India. The company works in other services, within the business services industry. It was incorporated on 29 December 2017 (9+ years old) and is registered under CIN U74999AS2017PTC018293.
Narzi Pharmaceuticals reported revenue of ₹15.51 Lakh for FY 2022 (up 1634% YoY).
Narzi Pharmaceuticals has 3 current directors:
- Faruk Choudhury - Director
- Jahangir Hussain - Director
- Amzad Hussain - Director
Narzi Pharmaceuticals reported a net profit of ₹6,134 (net margin 0.4%) and EBITDA of ₹11,448 (EBITDA margin 0.7%) for FY 2022, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Narzi Pharmaceuticals is 51% over three years. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Narzi Pharmaceuticals is 18AAFCN8889C1ZY, registered in Assam.
The CIN (Corporate Identification Number) of Narzi Pharmaceuticals is U74999AS2017PTC018293. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Narzi Pharmaceuticals was incorporated on 29 December 2017, making it 9+ years old. It is registered with the Registrar of Companies, Guwahati.
The peers of Narzi Pharmaceuticals by revenue are Regera Ventures Private Limited, Revolutionlife Pharmaceuticals Private Limited, Externa Pharmaceuticals Private Limited, PGRS New Life Pharma Private Limited, Orca Labs Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals).
Faruk Choudhury was appointed as Director on 31 May 2021. Amzad Hussain was appointed as Director on 29 Dec 2017. Jahangir Hussain was appointed as Director on 29 Dec 2017.
Yes, Narzi Pharmaceuticals is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).